WO1996001622A8 - New oral pharmaceutical formulation containing magnesium salt of omeprazole - Google Patents

New oral pharmaceutical formulation containing magnesium salt of omeprazole

Info

Publication number
WO1996001622A8
WO1996001622A8 PCT/SE1995/000816 SE9500816W WO9601622A8 WO 1996001622 A8 WO1996001622 A8 WO 1996001622A8 SE 9500816 W SE9500816 W SE 9500816W WO 9601622 A8 WO9601622 A8 WO 9601622A8
Authority
WO
WIPO (PCT)
Prior art keywords
omeprazole
magnesium salt
oral pharmaceutical
pharmaceutical formulation
formulation containing
Prior art date
Application number
PCT/SE1995/000816
Other languages
French (fr)
Other versions
WO1996001622A1 (en
Inventor
Siv Inga Bengtsson
Kurt Ingmar Loevgren
Original Assignee
Astra Ab
Siv Inga Bengtsson
Kurt Ingmar Loevgren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab, Siv Inga Bengtsson, Kurt Ingmar Loevgren filed Critical Astra Ab
Priority to BR9508261A priority Critical patent/BR9508261A/en
Priority to HU9700039A priority patent/HUT78132A/en
Priority to MX9700152A priority patent/MX9700152A/en
Priority to AU29947/95A priority patent/AU695723C/en
Priority to EE9700014A priority patent/EE03378B1/en
Priority to SK1660-96A priority patent/SK166096A3/en
Priority to PL95318464A priority patent/PL181265B1/en
Priority to NZ289958A priority patent/NZ289958A/en
Priority to JP8504257A priority patent/JPH10504288A/en
Priority to EP95926067A priority patent/EP0768872A1/en
Priority to CZ963795A priority patent/CZ379596A3/en
Priority to KR1019970700059A priority patent/KR970704426A/en
Publication of WO1996001622A1 publication Critical patent/WO1996001622A1/en
Priority to IS4398A priority patent/IS4398A/en
Priority to NO970036A priority patent/NO970036D0/en
Priority to FI970058A priority patent/FI970058A0/en
Publication of WO1996001622A8 publication Critical patent/WO1996001622A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

A new oral pharmaceutical formulation containing a novel physical form of a magnesium salt of omeprazole coated with one or more enteric coating layers, a method for the manufacture of such a formulation, the use of such a formulation in medicine and a blister package containing the new formulation.

Description

FOR THE PURPOSES OF INFORMATION ONLY
Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.
AT Austria GB United Kingdom MR Mauritania
AU Australia GE Georgia MW Malawi
BB Barbados GN Guinea NE Niger
BE Belgium GR Greece NL Netherlands
BF Burkina Faso HU Hungary NO Norway
BG Bulgaria IE Ireland NZ New Zealand
BJ Benin IT Italy PL Poland
BR Brazil JP Japan PT Portugal
BY Belarus KE Kenya RO Romania
CA Canada KG Kyrgystan RU Russian Federation
CF Central African Republic KP Democratic People's Republic SD Sudan
CG Congo of Korea SE Sweden
CH Switzerland KR Republic of Korea SI Slovenia
CI Cδte d'lvoire KZ Kazakhstan SK Slovakia
CM Cameroon LI Liechtenstein SN Senegal
CN China LK Sri Lanka TD Chad
CS Czechoslovakia LU Luxembourg TG Togo
CZ Czech Republic LV Latvia TJ Tajikistan
DE Germany MC Monaco TT Trinidad and Tobago
DK Denmark MD Republic of Moldova UA Ukraine
ES Spain MG Madagascar US United States of America
FI Finland ML Mali uz Uzbekistan
FR France
Figure imgf000002_0002
MN Mongolia
Figure imgf000002_0003
VN Viet Nam
Figure imgf000002_0001
GA Gabon
PCT/SE1995/000816 1994-07-08 1995-07-03 New oral pharmaceutical formulation containing magnesium salt of omeprazole WO1996001622A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
BR9508261A BR9508261A (en) 1994-07-08 1995-07-03 Enterically coated oral formulation using the same process to prepare the formulation to inhibit gastric acid secretion in mammals and humans and to treat gastric acid-related diseases in humans and humans and cross-pressure blister pack
HU9700039A HUT78132A (en) 1994-07-08 1995-07-03 New oral pharmaceutical formulation containing magnesium salt of omeprazole
MX9700152A MX9700152A (en) 1994-07-08 1995-07-03 New oral pharmaceutical formulation containing magnesium salt of omeprazole.
AU29947/95A AU695723C (en) 1994-07-08 1995-07-03 New oral pharmaceutical formulation containing magnesium salt of omeprazole
EE9700014A EE03378B1 (en) 1994-07-08 1995-07-03 Oral dosage form containing magnesium salt of omeprazole
NZ289958A NZ289958A (en) 1994-07-08 1995-07-05 Oral enteric coated medicament containing a magnesium salt of omeprazole having a degree of crystallinity which is higher than 70%, used to inhibit gastric acid secretion
PL95318464A PL181265B1 (en) 1994-07-08 1995-07-05 Novel pharmaceutic preparation for oral administration containing a magnesium salt of omeprasole
SK1660-96A SK166096A3 (en) 1994-07-08 1995-07-05 New oral pharmaceutical formulation containing magnesium salt of omeprazole
JP8504257A JPH10504288A (en) 1994-07-08 1995-07-05 Novel oral pharmaceutical formulations containing magnesium salt of omeprazole
EP95926067A EP0768872A1 (en) 1994-07-08 1995-07-05 New oral pharmaceutical formulation containing magnesium salt of omeprazole
CZ963795A CZ379596A3 (en) 1994-07-08 1995-07-05 Novel oral pharmaceutical preparation containing omeprazol magnesium salt
KR1019970700059A KR970704426A (en) 1994-07-08 1995-07-05 A New Oral Pharmaceutical Formulation Containing Magnesium Salt of Omeprazole Containing Magnesium Salt of Omeprazole
IS4398A IS4398A (en) 1994-07-08 1996-12-17 New oral oral formulations containing magnesium salt of omeprazole
NO970036A NO970036D0 (en) 1994-07-08 1997-01-06 New oral pharmaceutical preparation containing magnesium salt of omeprazole
FI970058A FI970058A0 (en) 1994-07-08 1997-01-07 A new oral pharmaceutical preparation containing the magnesium salt of omeprazole

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31320894A 1994-07-08 1994-07-08
SEPCT/SE94/00679 1994-07-08
SE9400679 1994-07-08

Publications (2)

Publication Number Publication Date
WO1996001622A1 WO1996001622A1 (en) 1996-01-25
WO1996001622A8 true WO1996001622A8 (en) 1999-12-23

Family

ID=20393105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1995/000816 WO1996001622A1 (en) 1994-07-08 1995-07-03 New oral pharmaceutical formulation containing magnesium salt of omeprazole

Country Status (15)

Country Link
EP (1) EP0768872A1 (en)
KR (1) KR970704426A (en)
BR (1) BR9508261A (en)
CA (1) CA2193681A1 (en)
CZ (1) CZ379596A3 (en)
EE (1) EE03378B1 (en)
FI (1) FI970058A0 (en)
HU (1) HUT78132A (en)
IS (1) IS4398A (en)
MX (1) MX9700152A (en)
NO (1) NO970036D0 (en)
NZ (1) NZ289958A (en)
PL (1) PL181265B1 (en)
SK (1) SK166096A3 (en)
WO (1) WO1996001622A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (en) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US5900258A (en) * 1996-02-01 1999-05-04 Zeolitics Inc. Anti-bacterial compositions
SI9700186B (en) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Novel pharmaceutical preparation with controlled release of active healing substances
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704870D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9802973D0 (en) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
CA2413923A1 (en) * 2000-03-09 2001-09-13 Andrew Ilchyshyn Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
ES2534713T3 (en) 2002-10-16 2015-04-27 Takeda Pharmaceutical Company Limited Stable solid preparations
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1755566A2 (en) * 2004-06-15 2007-02-28 Teva Pharmaceutical Industries Ltd Stable pharmaceutical formulations of benzimidazole compounds
CN105106168B (en) * 2015-08-19 2018-03-06 德州德药制药有限公司 A kind of esomeprazole magnesium intestines capsule and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (en) * 1988-05-18 1995-07-26 エーザイ株式会社 Oral formulation of acid labile compounds
SE9302396D0 (en) * 1993-07-09 1993-07-09 Ab Astra A NOVEL COMPOUND FORM
SE9302395D0 (en) * 1993-07-09 1993-07-09 Ab Astra NEW PHARMACEUTICAL FORMULATION

Also Published As

Publication number Publication date
KR970704426A (en) 1997-09-06
PL181265B1 (en) 2001-06-29
AU695723B2 (en) 1998-08-20
EP0768872A1 (en) 1997-04-23
NO970036L (en) 1997-01-06
EE03378B1 (en) 2001-04-16
HU9700039D0 (en) 1997-02-28
BR9508261A (en) 1997-12-23
AU2994795A (en) 1996-02-09
WO1996001622A1 (en) 1996-01-25
MX9700152A (en) 1997-04-30
PL318464A1 (en) 1997-06-09
FI970058A (en) 1997-01-07
CZ379596A3 (en) 1997-08-13
NZ289958A (en) 1998-09-24
FI970058A0 (en) 1997-01-07
SK166096A3 (en) 1997-09-10
HUT78132A (en) 2000-06-28
NO970036D0 (en) 1997-01-06
EE9700014A (en) 1997-06-16
IS4398A (en) 1996-12-17
CA2193681A1 (en) 1996-01-25

Similar Documents

Publication Publication Date Title
WO1996001622A8 (en) New oral pharmaceutical formulation containing magnesium salt of omeprazole
WO1997025042A8 (en) Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x
WO1997020575A8 (en) Targeted adenovirus vectors
WO1998010771A8 (en) Prevention of ovarian cancer by administration of progestin products
WO1997017980A8 (en) Treatment of cardiomyopathy by removal of autoantibodies
WO1998024183A8 (en) Mouse interface device for providing force feedback
WO1999045910A3 (en) Methods and compositions for treating and preventing mucositis
WO1998010386A8 (en) Disc-like device with eas material
WO1997013154A8 (en) Crossed coil gauge with active flux ring
WO1997048032A8 (en) Programmable metallization cell and method of making
WO1998022094A3 (en) Method for producing shaped and unshaped polyol masses
WO1998018888A8 (en) Refining of edible oil rich in natural carotenes and vitamin e
WO1998015622A8 (en) Transformation and regeneration of fertile cotton plants
WO1998025264A8 (en) Leading edge slider microactuator
WO1998016421A8 (en) Aircraft based sensing, detection, targeting, communications and response apparatus
WO1998000479A8 (en) Raffinate hydroconversion process
WO1999015684A8 (en) Expression of genes in hematopoietic stem cells in hischaemic conditions
WO1998009686A8 (en) Hydrobromocarbon blends to protect against fires and explosions
WO1998023962A8 (en) Diagnosis of prion diseases
WO1997020810A8 (en) Process for the preparation of 1-aryl-1-cyanocyclobutane derivatives
WO1998015272A8 (en) Method for inhibiting stress-activated protein kinases
WO1996013594A8 (en) Tumor-specific antibody fragments, fusion proteins, and uses thereof
WO1998023002A8 (en) Rack with a lower frame and an upper frame made of a continuous section
WO1998027107A8 (en) Method of coupling polysaccharides to proteins
WO1998001460A8 (en) Brca1 compositions and methods for the diagnosis and treatment of breast cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95194038.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 289958

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV1996-3795

Country of ref document: CZ

Ref document number: 166096

Country of ref document: SK

Ref document number: 2193681

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1019970700059

Country of ref document: KR

Ref document number: 970058

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1995926067

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995926067

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1996-3795

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019970700059

Country of ref document: KR

AK Designated states

Kind code of ref document: C1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 05/96 UNDER (22) REPLACE "05.07.95" BY "03.07.95"

WWW Wipo information: withdrawn in national office

Ref document number: 1995926067

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1996-3795

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1019970700059

Country of ref document: KR